Early detection and differential diagnosis of high-risk prostate cancer is imperative, so as to enable risk-stratification and decision-making in disease management. This research shows that the ECM oncoprotein Extradomain-B Fibronectin (EDB-FN) is strongly associated with high-risk prostate tumors and with low-risk prostate tumors that evolve into high-risk tumors, highlighting the potential of EDB-FN as a promising diagnostic biomarker for prostate cancer imaging. In addition, we have developed EDB-FN-specific peptide targeted MRI contrast agents that facilitate accurate differential detection and risk-stratification of prostate cancers.
This abstract and the presentation materials are available to members only; a login is required.